Furthermore, tissue immunofluorescence staining underscored the treatment’s efficacy in upregulating the M1 macrophage marker CD86 and downregulating the M2 macrophage marker CD163 within the tumor milieu (Figs. 6I, S3B). This evidence concerns the gene CD86 and neoplasm.